Ioachim E
Pathology Department, University of Ioannina, Medical School, Ioannina, Greece.
Histol Histopathol. 2008 Feb;23(2):187-96. doi: 10.14670/HH-23.187.
Thymidine phosphorylase (TP)/platelet-derived endothelial cell growth factor, stimulates chemataxis of endothelial cells and is involved in the angiogenesis of human solid tumours. In this study we investigated tissue sections from 93 breast carcinomas for the immunohistochemical expression of thymidine phosphorylase protein and in relationship to several clinicopathological parameters. The possible relationship to tumour neovascularization, VEGF expression, extracellular matrix components (tenascin, fibronectin, collagen type IV and laminin) and cathepsin D was also estimated. Nuclear and/or cytoplasmic TP expression was observed in tumour cells. Immunoreactivity was also often present in the stroma, endothelium and tumour-associated macrophages. High cytoplasmic TP expression, was observed in 35.5%, moderate in 30.1%, mild in 18.3%, while 16.1% of the cases were negative for TP expression. Moderate and high nuclear TP expression was observed in 30.1% of the tumours, low in 43%, while 26.9% did not show nuclear TP expression. High tumour stroma TP expression was expressed in 23.7% of the cases, moderate in 21.5%, mild in 45.2%, while 9.7% did not show stromal TP expression. TP expression did not correlate with the conventional clinicopathological features as well as with the microvessel density and the VEGF expression. Patients with high levels of tumour cell TP expression were significantly associated with a favorable outcome in univariate method of analysis. A positive correlation of TP expression with Cathepsin D expression was noticed. In addition, tumour cell TP expression was correlated with the extracellular matrix component tenascin, while stromal cell TP expression was correlated with the growth fraction of the tumour. Our data suggests that TP expression does not seem to affect directly the neovasculatur of breast carcinoma, although it seems to be implicated in the remodeling of breast cancer tissue, through the interaction with other extracellular matrix components or proteolytic enzymes. In addition, tumour cell TP expression could be considered as a prognostic indicator of breast cancer patients.
胸苷磷酸化酶(TP)/血小板衍生的内皮细胞生长因子,可刺激内皮细胞的趋化作用,并参与人类实体瘤的血管生成。在本研究中,我们调查了93例乳腺癌组织切片中胸苷磷酸化酶蛋白的免疫组化表达及其与几个临床病理参数的关系。还评估了其与肿瘤新生血管形成、VEGF表达、细胞外基质成分(腱生蛋白、纤连蛋白、IV型胶原和层粘连蛋白)以及组织蛋白酶D的可能关系。在肿瘤细胞中观察到核和/或细胞质TP表达。免疫反应性也常出现在基质、内皮和肿瘤相关巨噬细胞中。高细胞质TP表达见于35.5%的病例,中度表达见于30.1%,轻度表达见于18.3%,而16.1%的病例TP表达为阴性。30.1%的肿瘤观察到中度和高核TP表达,低表达见于43%,而26.9%未显示核TP表达。23.7%的病例肿瘤基质TP表达高,中度表达见于21.5%,轻度表达见于45.2%,而9.7%未显示基质TP表达。TP表达与传统临床病理特征以及微血管密度和VEGF表达均无相关性。在单变量分析方法中,肿瘤细胞TP表达水平高的患者与良好预后显著相关。注意到TP表达与组织蛋白酶D表达呈正相关。此外,肿瘤细胞TP表达与细胞外基质成分腱生蛋白相关,而基质细胞TP表达与肿瘤的生长分数相关。我们的数据表明,TP表达似乎并不直接影响乳腺癌的新生血管形成,尽管它似乎通过与其他细胞外基质成分或蛋白水解酶的相互作用参与乳腺癌组织的重塑。此外,肿瘤细胞TP表达可被视为乳腺癌患者的一个预后指标。